Abstract
Cancer is fundamentally a genomic disease caused by mutations or rearrangements in the DNA or epigenetic machinery of a patient. An emerging field in cancer treatment targets key aberrations arising from the mutational landscape of an individual patient’s disease rather than employing a cancer-wide cytotoxic therapy approach. In prostate cancer in particular, where there is an observed variation in response to standard treatments between patients with disease of a similar pathological stage and grade, mutationdirected treatment may grow to be a viable tool for clinicians to tailor more effective treatments. This review will describe a number of mutations across multiple forms of cancer that have been successfully antagonised by targeted therapeutics including their identification, the development of targeted compounds to combat them and the development of resistance to these therapies. This review will continue to examine these same mutations in the treatment and management of prostate cancer; the prevalence of targetable mutations in prostate cancer, recent clinical trials of targeted-agents and the potential or limitations for their use.
Keywords: Precision medicine, prostate cancer, targeted therapeutics.
Current Cancer Drug Targets
Title:Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Volume: 15 Issue: 5
Author(s): Ryan Stuchbery, Natalie J. Kurganovs, Patrick J. McCoy, Colleen C. Nelson, Vanessa M. Hayes, Niall M. Corcoran and Christopher M. Hovens
Affiliation:
Keywords: Precision medicine, prostate cancer, targeted therapeutics.
Abstract: Cancer is fundamentally a genomic disease caused by mutations or rearrangements in the DNA or epigenetic machinery of a patient. An emerging field in cancer treatment targets key aberrations arising from the mutational landscape of an individual patient’s disease rather than employing a cancer-wide cytotoxic therapy approach. In prostate cancer in particular, where there is an observed variation in response to standard treatments between patients with disease of a similar pathological stage and grade, mutationdirected treatment may grow to be a viable tool for clinicians to tailor more effective treatments. This review will describe a number of mutations across multiple forms of cancer that have been successfully antagonised by targeted therapeutics including their identification, the development of targeted compounds to combat them and the development of resistance to these therapies. This review will continue to examine these same mutations in the treatment and management of prostate cancer; the prevalence of targetable mutations in prostate cancer, recent clinical trials of targeted-agents and the potential or limitations for their use.
Export Options
About this article
Cite this article as:
Stuchbery Ryan, Kurganovs J. Natalie, McCoy J. Patrick, Nelson C. Colleen, Hayes M. Vanessa, Corcoran M. Niall and Hovens M. Christopher, Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer, Current Cancer Drug Targets 2015; 15 (5) . https://dx.doi.org/10.2174/1568009615666150416113453
DOI https://dx.doi.org/10.2174/1568009615666150416113453 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Some Recent Synthetic Development on Compounds with Potent Activities on Hormone-sensitive Breast Cancers
Current Organic Chemistry Multi-Target QSAR Approaches for Modeling Protein Inhibitors. Simultaneous Prediction of Activities Against Biomacromolecules Present in Gram-Negative Bacteria
Current Topics in Medicinal Chemistry Potentials and Challenges of Active Targeting at the Tumor Cells by Engineered Polymeric Nanoparticles
Current Pharmaceutical Biotechnology Nutritional Assessment in the Critically Ill Child
Current Pediatric Reviews Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets A Discussion of MicroRNAs in Cancers
Current Bioinformatics Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology Multiple Mechanisms of Cytokine Action in Neurodegenerative and Psychiatric States: Neurochemical and Molecular Substrates
Current Pharmaceutical Design Treatment of PSA only Recurrence of Prostate Cancer After Prior Local Therapy
Current Pharmaceutical Design MAPKs and Their Inhibitors in Neuronal Differentiation
Current Enzyme Inhibition Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances
Current Cancer Therapy Reviews Computational Models for 5αR Inhibitors for Treatment of Prostate Cancer: Review of Previous Works and Screening of Natural Inhibitors of 5αR2
Current Computer-Aided Drug Design Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Current Molecular Medicine Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond
Current Drug Targets MicroRNAs in Cancer Gene Therapy: Another Look
Current Cancer Therapy Reviews STAT 3 as a Target for Cancer Drug Discovery
Current Medicinal Chemistry Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer
Current Drug Targets